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Cancer cells are characterized by high glycolytic rates to support energy regeneration and anabolic
metabolism, along with the expression of pyruvate kinase isoenzyme M2 (PKM2). The latter
catalyzes the last step of glycolysis and reprograms the glycolytic ﬂux to feed the special metabolic
demands of proliferating cells. Besides, PKM2 has moonlight functions, such as gene transcription,
favoring cancer. Accumulating evidence suggests a critical role played by the low-activity-dimeric
PKM2 in tumor progression, supported by the identiﬁcation of mutations which result in the
down-regulation of its activity and tumorigenesis in a nude mouse model. This review discusses
PKM2 regulation and the beneﬁts it confers to cancer cells. Further, conﬂicting views on PKM2’s role
in cancer, its therapeutic relevance and future directions in the ﬁeld are also discussed.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Cancer metabolism and PKM2
The metabolism of cancer cells differs signiﬁcantly from normal
cells. As observed by Otto Warburg in 1924, cancer cells take up
high amounts of glucose and utilize it differently from normal cells
by producing lactate even in the presence of oxygen [1,2]. This
phenomenon is termed ‘‘Warburg effect’’ or ‘‘aerobic glycolysis’’.
At his time, Otto Warburg postulated a defect in mitochondrial res-
piration as a cause for the increased aerobic glycolysis in tumor
cells. However, as will be discussed later in this review, aerobic
glycolysis is now evaluated as a sophistication of cancer cells [3].
Glycolytic energy regeneration is independent of oxygen supply
and allows tumor cells to grow in areas with varying oxygen con-
centrations. In addition, cancer cells use large amounts of glucose
carbons for anabolic processes [4]. The high rates of glucose
conversion have been exploited in the clinical detection of tumors
by 18ﬂuorodeoxyglucose–positron emission tomography
(fDG–PET) and hyperpolarized 13C magnetic resonance imaging(MRI) [5–9]. Production of lactate, during aerobic glycolysis, has
the consequence of reduced pyruvate channelled into oxidative
phosphorylation [10]. The lactate produced is secreted out of the
cells to keep aerobic glycolysis active. Studies suggest a role of
secreted lactate in immune escape, migration, metastasis, tumor
vascularization and radioresistance [11–13].
Acute dependency of tumors on aerobic glycolysis has kept
cancer biologists wondering about its advantage to tumor cells.
Gatenby et al. in their review ‘‘Why do cancer cells have high aer-
obic glycolysis?’’ propose aerobic glycolysis as an adaptation to
hypoxic microenvironment in pre-malignant lesions [14]. Later
reviews discuss the evolutionary conserved preference for non-
oxidative metabolism for production of biomass and reason that
aerobic glycolysis is vital in maintaining macromolecular synthesis
[10,15].
M2 isoform of pyruvate kinase (PKM2) is a key regulator of the
metabolic fate of the glycolytic intermediates and has the unique
ability to shift glucose metabolism in favor of cancer cells
[10,16,17]. In accordance, cancerous state correlates with high
PKM2 expression in a variety of tumor tissues and cell lines [69].
Besides a crucial metabolic role, a large body of data have unrav-
elled the role of PKM2 in gene transcription and its ability to act
as protein kinase [18–22]. Due to the soaring number of papers
dealing with the role of PKM2 in cancer, PKM2 has gained enor-
mous attention and, here, we discuss PKM2 biology, in the light
of new developments, to comprehend its therapeutic relevance.
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The mammalian pyruvate kinase (PK) family is comprised of
two genes that encode four isoforms (L, R, M1 and M2). L and R
isoforms, present in liver and erythrocytes, respectively [23], are
encoded by PKLR gene using different promoters. M1 and M2
isoforms are alternative splicing products of the PKM gene. M1 is
mainly found in adult skeletal muscle and brain, while M2 is the
dominant isoform in proliferating cells [24]. The distribution of
the pyruvate kinase isoforms is tissue speciﬁc depending on the
metabolic necessities of the tissues. Constitutively active M1
isoform is expressed in muscle and brain tissues that need a large
supply of ATP. The isoform L is expressed in tissues with gluconeo-
genesis, such as liver, kidney and intestine. Cells and tissues with a
high rate of nucleogenesis are characterized by the expression of
the isoform M2. The existence of different PK isoforms reﬂects
the importance of the last step of glycolysis to cope with the differ-
ential metabolic requirements of cells.
The presence of PKM2 in embryonic tissues is a ﬁrst sign of its
importance for proliferating cells. PKM2 is the prototypic isoform
of pyruvate kinase and is gradually replaced by other tissue speciﬁc
isoforms during differentiation [17]. The replacement of PKM2 by
other isoforms during tissue differentiation is indicative of a mech-
anism that ensures the strict regulation of PKM2 expression during
development. Several studies have reported an isoform shift back
to PKM2 during tumor formation. L to M2 shift is reported to be
a late event in hepatocarcinogenesis [25]. Christofk et al. demon-
strated that the switch from M1 to M2 is required for aerobic gly-
colysis [26]. They further described that tumor growth diminished
when PKM2 was replaced by PKM1, thereby concluding that the
switch to PKM2 is necessary for cancer metabolism and tumor
growth. However, these results do not correlate with the presence
of PKM2 in some differentiated tissues, i.e. lung, adipose, pancre-
atic islets, retina, distal renal tubules, Henle´s loops and renal
collecting tubules, blood vessel walls, bile duct epithelium, and
sinusoidal lining cells in the liver [27,69]. Using the cancer genome
atlas, RNA-Seq, and exon array datasets, Desai et al. showed ele-
vated PKM2 expression in sixteen different tumor types compared
to their normal counterparts [28]. They observed an isoform switch
from PKM1 to PKM2 (at mRNA level) only in glioblastomas and not
in other cancer types. However, in this study, PK isoform expres-
sion among the different cell types within the particular tissues,
i.e. the tubules system in the kidney or the different cell types in
the liver [27,29] have not been taken into account.
3. PKM gene and its expression
Understanding the regulation of PKM2 expression is of para-
mount importance for it is how PKM2 integrates into the cellular
scenario. The PKM locus encodes for the mutually exclusive M1
and M2 isoforms of pyruvate kinase [24]. These isoforms result
from alternative splicing of the PKM pre mRNA into the M1 (with
exon 9) and M2 (with exon 10) isoforms. Both isoforms differ only
in 22 out of 531 amino acids and the exon that is exchanged
encodes for 56 amino acids [24]. This region forms the inter-subunit
contact domain (ISCD) of PKM2,which is involved in the association
of dimers into tetramers [30].
Since the metabolic implications of M1 and M2 are different
[17], PKM gene splicing is tightly regulated to ensure appropriate
isoform expression. Oncogenic c-Myc in cancer cells has been
shown to dictate splicing machinery for inclusion of exon 10 to
ensure high PKM2/PKM1 ratio and thus regulate PKM splicing in
favor of PKM2 [31]. Recently, it is reported that growth factor sig-
naling via PI3K/Akt/mTOR upregulates the expression of PKM2
through HIF1a/c-Myc axis to promote Warburg effect and tumorgrowth [32]. Glucose is al‘so reported to favor PKM2 expression in
rat hepatoma cell line and isolated adipocytes [33,34]. Furthermore,
hormones like insulin, triiodothyronine (T3), and glucocorticoids
also regulate PKM gene expression in order to attain the required
metabolism in the cell [35–37]. We have shown that insulin
up-regulates PKM2 expression but decrease its activity to promote
cancermetabolism [38]. Since insulin signaling has been implicated
in cancer [39], it could therefore be conjectured that insulin, at least
in part, contributes to cancer metabolism by regulating PKM2 state
[38].
Hypoxia, a common feature of most tumors, induces upregula-
tion of PKM gene expression via stabilization of transcription factor
HIF1a [40]. Besides hypoxic induction, HIF1a accumulation is also
induced by glycolytic metabolites in aerobic conditions, eventually
resulting in induction of HIF1 target genes [41]. Hypoxic induction
of PKM2 may underlie the resistance of hypoxic tumor cells to
chemo and radiotherapy [42,43].
Epigenetic alterations by hypomethylation of intron 1 in the
PKM gene are also reported to correlate with elevated PKM2
expression in tumors [28]. The complex regulation of the PKM gene
ensures the expression of PKM2 upon requirement, especially
during neonatal stages. Cancer cells appear to exploit this very
regulation of PKM2 in their favor through oncogenic and dysregu-
lated growth factor signaling.
4. Bifunctional role of PKM2 in glycolysis
Glycolysis (glucose lysis) is a central metabolic pathway in both
prokaryotes and eukaryotes. It feeds energy regeneration and
anabolism. In differentiated tissues, such as muscle, pyruvate, the
end product of glycolysis, is channelled into the Krebs cycle
followed by oxidative phosphorylation during respiration [44].
Further, in several cell types, the intermediates of glycolysis like
glucose-6-phosphate, fructose-6-phosphate, glyceraldehyde-
3-phosphate, dihydroxyacetone-P, glycerate 3-P are required for
biosynthetic pathways of nucleic acid, phospholipid, amino acid
and sphingolipids synthesis. [45].
Pyruvate kinase M2 catalyzes the last step of glycolysis; the
conversion of phosphoenolpyruvate (PEP) to pyruvate with con-
comitant production of ATP [46]. The ATP generation by PKM2,
unlike mitochondrial respiration, is independent of oxygen and
thus allows tumor cells to grow in hypoxic conditions. Also, the
position of PKM2 in the glycolytic sequence is instrumental in reg-
ulating the metabolic fate of the glycolytic intermediates. PKM2
activity, if high, results in rapid conversion of PEP to pyruvate with
regeneration of energy [47]. In contrast, decreased PKM2 activity
leads to an expansion of all glycolytic intermediates above the
pyruvate kinase reaction, which are then available as precursors
for synthetic processes that offshoot from glycolysis. The ability
of PKM2 to redirect glucose ﬂux in glycolysis is controlled by its
allosteric activator fructose 1,6-bisphosphate (FBP) [48]. Binding
of FBP to PKM2 increases its afﬁnity towards its substrate PEP
[49]. Thus, the position of PKM2 within the glycolytic sequence
makes it a ‘‘glycolytic valve’’ in deciding the direction of glucose
ﬂux in glycolysis.
5. Inactive and active oligomeric forms of PKM2: activity
regulation
PKM2 exists in two oligomeric forms- tetrameric and dimeric.
The tetrameric form of PKM2 has a high afﬁnity to PEP and is
highly active whereas the dimeric form is characterized by a low
PEP afﬁnity and is nearly inactive, under physiological conditions
[17] On requirement, the tetramer dissociates into less active
dimers or the dimers associate to the tetrameric form. An
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At high levels, FBP induce the association of two dimers into a
highly active tetrameric PKM2. The ratio between the tetrameric
and dimeric form of PKM2 decides the overall activity of PKM2
in cellular milieu [46] and thus the glycolytic ﬂux towards catabo-
lism or anabolism. The tetramer: dimer ratio is also regulated by
post-translational modiﬁcations as well as interactions with onco-
proteins which favor the inactive dimeric form of the enzyme [17].
Post-translational modiﬁcations in the A-domain of PKM2 play
a key role in subunit dissociation thereby resulting in reduced
activity (Fig. 1A). The tyrosine-105-phosphorylation of PKM2 by
oncogenic tyrosine kinases inhibits its activity by causing the
release of its allosteric activator FBP (Fig. 1B) [50]. Xenograft tumor
model studies have shown that tyrosine-105-phosphorylation-
induced decline in PKM2 activity promoted tumor growth [50].
Lv et al. described that acetylation of PKM2 at lysine-305 is respon-
sible for a downregulation of its activity (Fig. 1B). Interestingly,Fig. 1. Post-translational modiﬁcations in PKM2 and the metabolic implications. (A) Sche
M2; The interface of the A and B domain shows the presence of an active site (ACS); the C
the allosteric activator FBP. (B) Scheme of how different factors dictate various post-tr
tumor metabolism. Brieﬂy, the phosphorylation of tyrosine 105 carried out by tyrosine
high glucose concentration; and oxidation of cysteine-358 residue by intracellular RO
contributing to aerobic glycolysis in tumor. Abbreviations: FGFR1 – ﬁbroblast growth fa
oncogene homolog 1), JAK2 – janus kinase 2, FLT3 – fms like tyrosine kinase 3, ROS – reactihigh glucose concentrations induced K305 acetylation to funnel
the glucose into anabolic synthesis [51]. Furthermore, the authors
demonstrated that the acetylation-induced decrease in PKM2
activity promotes glycolytic pooling, NADPH synthesis, and even-
tually tumor growth [51]. Study by Anastasiou et al. revealed a
remarkable role of oxidized PKM2 in reducing oxidative stress in
cancer cells. In this paper, the authors report that intracellular
reactive oxygen species (ROS)-induced oxidation of cysteine-358
decreased its activity to divert glucose ﬂux into anabolic pentose
phosphate pathway, thereby generating sufﬁcient reducing poten-
tial for detoxiﬁcation of ROS (Fig. 1B) [52]. Moreover, the authors
show that oxidized-PKM2, through its lower activity, promotes
tumor growth, which was inhibited when mice were fed on
N-acetyl-L-cysteine (NAC; a potent scavenger of reactive oxygen
species, ROS). This report extended the relevance of PKM2 to
cancer and also emphasized the important role of this enzyme in
cancer. Besides post-translational modiﬁcations, numerous viralmatic organization of the various domains of the glycolytic enzyme pyruvate kinase
domain contains a nuclear localization signal sequence (NLS) and the binding site for
anslational modiﬁcations in PKM2, followed by the downstream consequences on
kinases-FGFR1, BCR-ABL, JAK-2 and FLT-3; acetylation of lysine-305 residue due to
S, facilitates the generation of enzymatically inactive dimers of PKM2, eventually
ctor receptor-1, BCR-ABL – (breakpoint cluster region-abelson murine leukemia viral
ve oxygen species.
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HPV 16 E7, are known to interact with PKM2 and modulate its tet-
rameric structure (reviewed in detail [16,46]). Recently, CD44
adhesion molecule, a surface marker of cancer stem cells, has been
shown to negatively regulate the PKM2 activity and thus contrib-
utes to aerobic glycolysis [53,54]. Evidently, decrease in PKM2
activity helps tumor cells in fulﬁlling their metabolic needs.
6. Non-metabolic functions of PKM2 – unorthodox roles
Apart from its essential metabolic role, PKM2 also contributes
to the process of tumorigenesis through its ‘‘non-metabolic’’ attri-
butes. PKM2 is reported to interact with the C-terminal residues ofFig. 2. Nuclear PKM2 and its functions. The illustration shows the factors responsible fo
acts as a transcriptional co-activator or as a protein kinase inside the nucleus to fa
phosphorylates PKM2 at serine 37 residue (S37), enabling its import into the nucleus t
catalyzed 403/408 proline hydroxylated PKM2 and JMJD5–PKM2 heterodimer complex in
self transactivate to establish a positive feedback loop. Furthermore, lysine 433 acetylatio
as a protein kinase by phosphorylating Stat3 and histone H3, thus, facilitating transcrip
prolyl hydroxylase 3, ERK1/2 – extracellular signal regulated kinase 1/2, EGF – endothelial gro
factor, PTB – polypyrimidine tract-binding protein, JMJD5 – jumonji C domain-containing diox
transporter 1, PDK1 – pyruvate dehydrogenase kinase, H3 – histone 3, HIF – hypoxic induciOct-4 and enhances its transactivation [55]. Oct-4 protein is impor-
tant in maintaining pluripotency in embryonic stem cells. In a
study published in Cell by Luo et al., nuclear PKM2 has been shown
to interact with its transcriptional activator HIF1a in a prolyl
hydroxylase 3 (PHD3) dependent manner. This interaction
increases transcriptional activity of HIF1a which results in higher
expression of its (HIF1a) target genes e.g. GLUT1 (glucose trans-
porter), LDHA (lactate dehydrogenase A) and PKM2 (Fig. 2). The
authors, thus, provide a possible explanation to the previous obser-
vations that a switch to PKM2 correlated with increased glucose
uptake and lactate production (aerobic glycolysis). Further, they
unravel a ‘‘positive feedback loop’’ mechanism that reprograms
glucose metabolism [18]. Wang et al. identiﬁed that Jumonji Cr nuclear localization of PKM2 and the non-metabolic implications. In short, PKM2
cilitate the expression of genes important for cell division. EGF-induced ERK1/2
o aid the transactivation of b-catenin target genes such as c-Myc. Likewise, PHD3
teracts with HIF1a and initiate its transcriptional activation of glycolytic genes; and
n of PKM2 by P300 localizes it to the nucleus, which enables the PKM2 dimer to act
tion of genes that are important for tumor cell proliferation. Abbreviations: PHD3 –
wth factor, P300 – histone acetyltransferase, LCF/TCF – lymphoid enhancing factor/T-cell
ygenase, LDHA – lactate dehydrogenase A, PKM2 – pyruvate kinase M2, GLUT1 – glucose
ble factor, STAT 3 – signal transducer and activator of transcription 3.
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PKM2, disrupts its tetrameric structure, inhibits activity and pro-
motes its nuclear translocation. Inside the nucleus, JMJD5–PKM2
heterodimer promotes HIF1a – mediated transactivation for meta-
bolic reprogramming [56].
Another letter in Nature by Yang et al. identiﬁed the role of
PKM2 in transcriptional activation in response to epidermal
growth factor (EGF). The authors report that PKM2 associates with
p-Tyr peptides of b-catenin in response to EGF stimulation, and
that this complex translocates into the nucleus where it localizes
to the cyclin D1 (CCND1) and c-Myc promoters (Fig. 2) [19].
PKM2-b-catenin complex enhances cyclin D1 and c-Myc expres-
sion through dissociation of HDAC3, a histone deacetylase, from
the CCND1 promoter. PKM2-dependent b-catenin transactivation
is involved in EGFR promoted tumor cell proliferation and develop-
ment. Upregulation of c-Myc expression by PKM2 forms a feed-
forward loop, since c-Myc has been shown to upregulate transcrip-
tion of heterogeneous nuclear ribonucleoproteins (hnRNPs) that
promote the alternative splicing of PKM2 over PKM1 [31]. Later,
Yang et al. found that PKM2 interacts and phosphorylates histone
H3 at threonine 11 residue upon EGF stimulation, which favors dis-
sociation of HDAC from the cyclin D1 and c-Myc promoters and
facilitates the H3-K9 acetylation (Fig. 2). This paper reports PKM2
as a protein kinase involved in histone modiﬁcations to control the
expression of c-Myc and cyclin D1 in cancer cells upon EGF stimu-
lation [57]. Further, nuclear PKM2 levels were found to be corre-
lated with H3/T11 phosphorylation status in glioma malignancy
grades. However, the mechanism controlling the switch between
pyruvate kinase and protein kinase functions of PKM2 remained
unclear.
A recent article in Molecular Cell reported that PKM2 dimer is a
protein kinase and that it regulates gene transcription [20]. The
authors demonstrated that PKM2 dimer is an active protein kinase
(with PEP as phosphate donor), while PKM2 tetramer is a pyruvate
kinase. Further, they showed that expression of a PKM2 mutant,
which exists as dimer, promotes cellular proliferation indicating
that its protein kinase activity is essential for cellular proliferation.
This study exposed an important link between metabolic transfor-
mation and gene expression.
Lv et al. described that acetylation at K433 dictates PKM2 to act
as a protein kinase rather than pyruvate kinase by inducing its
nuclear accumulation. Upon mitogenic or oncogenic stimulation,
p300 acetyltransferase catalyzes K433 acetylation of PKM2. Conse-
quently, K433 acetylated PKM2 fails to respond to its allosteric
activator FBP. This study further postulates the involvement of
K433 acetylated PKM2 in the promotion of cancer cell proliferation
by phosphorylation of STAT3 and Histone-3 and initiating a down-
stream transcriptional network (see Fig. 2) [58]. Besides PKM2’s
role in regulating the expression of the cell cycle protein cyclin
D1, direct involvement of PKM2 in the regulation of cell cycle pro-
gression has also been identiﬁed. PKM2 is shown to phosphorylate
spindle-checkpoint protein Bub3 at Y207, to assist formation of
Bub3-Bub1-Blinkin complex for correct kinetochore microtubules
attachment and proper chromosomal segregation [59]. This study
highlighted yet another protein kinase function of PKM2. Most
recently, SAICAR has been reported to bind and induce protein
kinase activity of PKM2. Moreover, SAICAR–PKM2 complex is
shown to phosphorylate several proteins (e.g. EGFR/MAPK signal-
ing proteins) that are important in proliferation [60]. Apart from
protein kinase function, PKM2 is also involved in generation of
cAMP via interaction with soluble adenylyl cyclase (sAC). The
cAMP produced induces EPAC/RAP1 mediated upregulation of b1
integrin pathway resulting in loss of cell polarity [61]. The complex
modiﬁcations of PKM2 along with its pyruvate and protein kinase
activity orchestrate the events necessary for cancer development.7. PKM2 as a therapeutic target
Targeting metabolic behavior of cancer cells is emerging as a
new avenue in cancer therapeutics [62,64]. Several metabolic tar-
gets are under preclinical and clinical trials [63,64]. Owing to the
array of beneﬁts PKM2 provides to tumor cells, it is emerging as
an attractive target in cancer therapy [65]. This section will review
the approaches targeting PKM2 expression and activity along with
their advantages and pitfalls.
7.1. RNAi (targeting the expression of PKM2)
siRNA speciﬁcally targeting PKM2 was shown to attenuate
growth and induce caspase-dependent apoptosis in several cancer
cell lines. Additionally, intra-tumoral injection of siRNA reduced
tumor growth of established tumor xenograft [66]. Further, Knock-
down of PKM2 by RNAi synergized with the efﬁcacy of the antican-
cer drugs- docetaxel and cisplatin in A549 lung cancer cell line and
mouse model [67,68]. Since PKM2 is also present in normal prolif-
erating and adult stem cells, chances of non-speciﬁc targeting in
normal cell could be a drawback in this approach [16,69]. Also,
silencing of PKM2 may mimic inactive PKM2 state, which is rather
beneﬁcial to proliferating cells. A decrease in PKM2 expression and
activity has been associated with drug resistance in various cancer
cell lines [70–73]. A plausible explanation for this correlation could
be that low PKM2 level results in the pooling and shunting of gly-
colytic intermediates to the pentose pathway to produce reducing
equivalent (NADPH and GSH), thus keeping the anti-oxidative
system active.
7.2. Inhibition of PKM2 activity
The idea behind this approach is that proliferating cells strongly
depend on energy and that inhibition of PKM2 inhibits energy
regeneration. Vander Heiden et al. performed a high throughput
screen and identiﬁed small molecules selectively inhibiting
PKM2. One of the identiﬁed compounds, (N-(3-carboxy-4-
hydroxy) phenyl 1-2,5,-dimethylpyrole), inhibited PKM2 activity
with IC50 in lM range and induced apoptosis in H1299 cells. Allo-
steric activation of PKM2 by FBP was also signiﬁcantly inhibited by
this compound, suggesting its interference with the allosteric FBP
binding loop in PKM2 [74]. Another compound named Arava,
which is known for inhibiting key enzyme in pyrimidine synthesis,
binds to PKM2 and decreases its activity by inducing M2 dimeriza-
tion in rat Novikoff hepatoma cells [75]. Natural drugs like Shikonin
and its analog Alkanin selectively inhibit PKM2 activity and induce
cell death in PKM2, but not PKM1, expressing cells [76]. However,
the PKM2 inhibition by these drugs is partially reversed by
addition of FBP to protein lysates.
The effects of these drugs on the tumor promoting non-glycolytic
functions of inactive nuclear PKM2 are not known and should be
studied. PKM2 inhibition may result in glycolytic accumulation
required for anabolic synthesis. In addition, glycolysis is not the only
source for energy regeneration in tumor cells. Most tumor cells are
characterized by high glutaminolytic capacities, thus, glutaminoly-
sis may be an escape mechanism for drugs inhibiting PKM2 [77].
7.3. PKM2 activation
Besides energy, proliferating cells strongly depend on the syn-
thesis of cell building blocks that is favored by the less active
dimeric PKM2. Thus, activation and ﬁxation of PKM2 in the highly
active tetrameric form may also inhibit cell proliferation due to the
resultant deﬁciency of precursors for the synthesis of cell building
blocks. In a recent study by Anastasiou et al., two representative
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and substituted N,N-diarylsulfonamide, were found to be potent
activators of PKM2 [78,79]. These chemical entities are cell perme-
able analogs that largely resemble the FBP-allosteric activator of
PKM2. These compounds activated PKM2 with AC50 value of
26–99 nM and reduced the Km for substrate PEP by 10-fold without
affecting the Vmax. Interestingly, the activation of PKM2 altered
cancer metabolism in vitro and reduced xenograft tumor growth.
Another study by Walsh et al. showed that 2-Oxo-N-aryl-1,2,3,
4-tetrahydroquinoline-6-sulfonamides activated PKM2, with AC50
in the range of 90 nM and 5-fold reduced Km for PEP [80].
The irreversible inactivation of PKM2 by modiﬁcations like
Y105 or by mutations could pose a problem in targeting modiﬁed
PKM2 for activation by chemical compounds. Alternatively,
upstream factors, which facilitate the formation of dimeric PKM2,
could be targeted in place of PKM2 itself (inhibition of formation
of dimeric PKM2 would result in high activity PKM2 tetramers).
Studies have shown that targeting the oncogenic tyrosine kinase
BCR–ABL with Imatinib, JAB2 by AG490 and FLT3 by TKI258 inhibit
tyrosine-105 phosphorylation of PKM2, thereby preventing its
inactivation [50].
Taken together, a multitude of studies indicate that PKM2 is a
promising target for therapeutic approaches. However, presence
of PKM2 in normal cells and existence of metabolic escape mecha-
nisms could limit the efﬁcacy of these approaches. Hence, there is a
need for the development of therapeutic strategies based on
metabolic individualization of tumors.
8. Evidences challenging the role of PKM2 in cancer
In the past 5 years, extensive research has unravelled a notable
involvement of PKM2 in cancer via its canonical and non-canonical
functions. However, some recent studies revealed controversial
observations about the role of PKM2 in cancer. For example,
knock-down of PKM2 resulted in a modest inhibitory effect on
in vitro proliferation of cancer cells and the xenograft tumors with-
out any signs of inhibition, suggesting that PKM2 is not an obliga-
tory requirement for tumor growth [81]. A latest Cell paper
describes that breast tumors in a PKM2 conditional mouse model
progressed faster despite PKM2 deletion, and that proliferation
within the PKM2 null mice was associated with PKM1 expression
[82], which is not consistent with the earlier ﬁnding that PKM1
expression and pyruvate kinase activators can suppress tumor
growth [82,83]. The authors discuss that following PKM exon 10
deletion, the tumors may create analogous states of high and low
pyruvate kinase activity by titrating the expression of PKM1. The
presence of loss-of-function heterozygous PKM2 mutations in
human cancers further supports this notion. In addition, the
authors refer to a possible pyruvate kinase independent mecha-
nism for conversion of PEP to pyruvate. The results may also imply
that the non-metabolic functions of PKM2, i.e. nuclear functions,
are not absolutely necessary for tumor cell proliferation [82].
Accordingly, nuclear translocation of PKM2 induced by somato-
statin analogues has been linked with apoptosis long before the
documentation of the tumor promoting consequences of nuclear
PKM2 [84].
9. Conclusion and future directions
In the last decade, a bursting number of publications revealed a
manifold role of PKM2 within tumor cells. However, there are still
voids that need to be ﬁlled in before we completely understand its
role in cancer. The recent evidence of the presence of loss-of-function
PKM2 mutations in some tumors, as well as our observation that
natural heterozygous mutations in PKM2 (observed in BloomSyndrome background) impair its activity [85] and promote tumor
growth [86], uphold the notion that lowered PKM2activity is critical
for tumor growth. Observations of dimeric PKM2 acting as a protein
kinase in regulation of gene expression further indicate its impor-
tance toproliferating tumor cells [20].However, it is yet to be known
if dimeric PKM2 promotes processes like migration and metastasis,
to further assist cancer. Also, it seems pertinent to explore if the
genetic variations in PKM2 that are responsible for hindering its
tetrameric structure increase cancer risk.
It has been known for a long time that dimeric PKM2 (M2-PK) is
present in plasma of cancer patients and that the dimeric M2-PK
plasma concentrations correlate with staging [87–89]. Besides,
PKM2 is also detectable in the stool from patients of lower gastro-
intestinal tract cancer and is used for colorectal cancer (CRC)
screening [90]. In CRC patients high sera M2-PK values correlate
with poor response to 5-FU-based chemotherapy [91]. In the fol-
low-up studies, PKM2 plasma levels have been shown to drop after
complete remission and increase in case of a local relapse [90,92].
Further, Duan et al. have shown that PKM2 binds to tumor endo-
thelial marker 8 (TEM8), which is located on the cell surface of
endothelial cells [93]. They discuss that PKM2 released from the
tumor might stimulate angiogenesis by binding to TEM8. These
studies warrant the investigation of extracellular PKM2 and the
potential role it might play in promoting cancer.
Most recent evidence showing that some tumor cells may not
require PKM2 for their growth are noteworthy in emphasizing
the need of a better understanding of metabolic heterogeneity in
tumor cells to envisage improved therapeutic strategies. Further,
possible heterogeneity among tumor cells with regards to oligo-
meric status of PKM2 may be challenging in therapeutic targeting
of its activity. Abnormal vascularization in tumors gives rise to
regions with low nutrient access; cells in this region, being essen-
tially quiescent, might express active tetrameric PKM2 which is
rather ﬁt for generation of survival ATP through glycolysis. How-
ever, at some point during tumorigenesis, changes in nutrient
availability and vascularization may result in conversion of active
PKM2 into inactive one; for instance, high glucose is known to
induce PKM2 acetylation thereby decreasing its activity. Active
PKM2 in quiescent cells may be contributory to chemoresistance
and relapse, since these cells are resistant to standard chemother-
apy regimens, and therefore, cause tumor relapse [94]. Regardless,
therapeutic activation of PKM2 seems promising at least in
inhibiting the metabolism of proliferating tumor cells; however,
it is yet to be known if this holds true for most tumor types.
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